Panel Discussion on ‘Advances in Drug Delivery: Modes, approaches and regulatory challenges’ | FDD Conclave 2022

Panelists in this video:
+ Mr Anil Kumar R, Sr VP – R&D, Strides Pharma Sciences
+ Dr Alagumurgan Alagarswamy, VP and Head R&D, Maiva Pharma
+ Dr Chandrasekhar Kandi, Sr VP-Formulations, Aurobindo Pharma
+ Dr Pavan Bhat, Executive VP, Natco Pharma
+ Dr Sajeev Chandran, Director, Adv. Drug Delivery Research & IVIVC / Biopharmaceutics, Pharma R&D, Lupin

Moderator:
+ Dr Ajay Khopade, VP – FR&D, Sun Pharma

Key Highlights:
+ If a technology is bridging a gap in drug delivery, regardless of its complexities, it is here to stay: Dr Ajay Khopade, VP- FR&D, Sun Pharma

+ It is important to create better synergies between regulatory agencies and industry to enable innovation in drug delivery and make it more effective and patient-centric: Anil Kumar R, Sr VP-R&D, Strides Pharma Sciences

+ The pandemic has accelerated advancements in drug delivery, especially in self-administered medicines and connected drug delivery devices: Dr Alagumurgan Alagarswamy, VP and Head R&D, Maiva Pharma

+ Ease of administration is a key need which is driving transformation in the drug delivery segment: Dr Chandrasekhar Kandi, Sr VP-Formulations, Aurobindo Pharma

+ The relevance and applicability of newer technologies like 3D printing and continous manufacturing need to be considered carefully before adoption: Dr Pavan Bhat, Executive VP, Natco Pharma

+ Even incremental advancements or innovation in drug delivery can lead to better patient compliance and improved therapeutic outcomes: Dr Sajeev Chandran, Director, Adv. Drug Delivery Research & IVIVC/ Biopharmaceutics, Pharma R&D, Lupin